Ophthalmic Medical Devices / Premium Intraocular Lenses (IOL)
Strategic Profile
RxSight has rapidly scaled adoption to reach 15% of North American cataract surgeons with LAL procedures capturing over 10% of the regional premium IOL market. The company's strategy focuses on clinical validation, surgeon education, device installation expansion (1,084 units installed base), and international expansion to unlock higher market penetration and drive gross margins toward 73-74%.
Cyborg Score Rationale
RxSight demonstrates strong revenue growth (57% in 2024, 57% of 2025 midpoint guidance) and expanding unit adoption, but faces near-term challenges including 2025 guidance cuts (down 25-31% from original), negative profitability with ongoing losses, and market skepticism evident in stock price decline from $37.13 52-week high to ~$10. The company requires successful execution on margin expansion and international rollout to achieve profitability.
Top Insights
Strong LAL procedure volume growth (+13% YoY to 27,380 in Q2 2025) despite revenue pressure from LDD sales decline (-49% YoY), indicating product adoption outpacing monetization
Significant guidance reduction for 2025 (from $160-175M to $120-130M) signals execution challenges, though gross margin improvement to 72-74% shows path to profitability
LDD installed base growing rapidly (+34% to 1,084 units), creating recurring revenue foundation for future LAL sales and higher-margin service revenue
Board reinforced with senior medtech talent (Raymond Cohen from Axonics/Boston Scientific) signaling investor confidence in turnaround potential and international scaling capability
Named Competitors
Laser-Assisted Cataract Surgery Systems — Pre-operative cataract surgery optimization technology
Premium IOL Products — Traditional premium intraocular lenses and vision correction platforms
Premium Cataract Surgery Solutions — Comprehensive cataract and vision correction products
Recent Developments
(March 2026) Stock trading near $10 after 52-week decline from $37, reflecting market repricing of profitability expectations
(February 2026) Piper Sandler raised price target to $11 from $10, maintaining analyst support despite recent headwinds
(March 2025) Board member Raymond Cohen orchestrated $600M sale of SoniVie Ltd. to Boston Scientific, bringing scaling expertise
(January 2025) RxSight reported 2024 full-year revenue of $139.9M (+57% YoY) and revised 2025 guidance downward to $120-130M from initial $160-175M
Open the full interactive RxSight, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.